939 Who May Have Treatment Benefits With Fibrates in Primary Biliary Cirrhosis: A Single Center Retrospective Observational Cohort Analysis

Komori, Akira; Nakamura, Monica Rika; Aiba, Yoshihiro; Kugiyama-Yasunaga, Y.; Bekki, S.; Sasaki, Ryuichiro; Hashimoto, Sunao; Ootani, Masahiko; Bae, Sunjae; Saeki, Akiko; Nagaoka, Shinya; Abiru, Seigo; Yamasaki, Kazumi; Ishibashi, Hisao; Yatsuhashi, Hiroshi

doi:10.1016/s0168-8278(13)60941-1

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large, randomized, placebo-controlled study is not yet available to support the use of fibrates as adjuvant therapy in PBC. Of note, marked inflammatory activity, stage IV fibrosis and severe ductopenia have been associated with lack of response (173) . Thus, like UDCA, fibrates also seem to be more beneficial in patients with early PBC (histological stages I and II).…”

Section: Rotterdammentioning

confidence: 99%

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver

Bittencourt

Cançado

Couto

et al. 2015

Arq. Gastroenterol.

View full text Add to dashboard Cite

-In order to draw evidence-based recommendations concerning the management of autoimmune diseases of the liver, the Brazilian Society of Hepatology has sponsored a single-topic meeting in October 18th, 2014 at São Paulo. An organizing committee comprised of seven investigators was previously elected by the Governing Board to organize the scientific agenda as well as to select twenty panelists to make a systematic review of the literature and to present topics related to the diagnosis and treatment of autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis and their overlap syndromes. After the meeting, all panelists gathered together for the discussion of the topics and the elaboration of those recommendations. The text was subsequently submitted for suggestions and approval of all members of the Brazilian Society of Hepatology through its homepage. The present paper is the final version of the reviewed manuscript organized in topics, followed by the recommendations of the Brazilian Society of Hepatology.

show abstract

Section: Rotterdammentioning

confidence: 99%

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver

Bittencourt

Cançado

Couto

et al. 2015

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Further, bezafibrate was shown to have anticholestatic and PXR agonist activity [29]. Up to now, all the reports have shown that bezafibrate or fenofibrate improved liver biochemistries in PBC [30]. …”

Section: Adjuvant Therapiesmentioning

confidence: 99%

Evidence-Based Treatment of Primary Biliary Cirrhosis

Poupon¹

2014

Dig Dis

View full text Add to dashboard Cite

The natural history of primary biliary cirrhosis (PBC) has improved greatly during the past two decades because of its diagnosis at earlier stages and the widespread use of ursodeoxycholic acid as first-line treatment. As a result, far fewer patients require liver transplantation and patients diagnosed with early-stage disease appear to have a normal life expectancy. The evidence-based treatment of PBC is reviewed here. The challenge of designing and executing high-quality clinical trials as well as lessons from past clinical trials are discussed. The rationales for the use of budesonide and new investigational therapies (PPAR and FXR agonists) as well as their therapeutic potential in light of recent available data are also reviewed. An algorithm of the management of PBC patients responding or not to ursodeoxycholic acid is proposed.

show abstract

Novel Therapies on Primary Biliary Cirrhosis

Czul

Levy

2016

Clinics in Liver Disease

View full text Add to dashboard Cite

939 Who May Have Treatment Benefits With Fibrates in Primary Biliary Cirrhosis: A Single Center Retrospective Observational Cohort Analysis

Cited by 5 publications

References 0 publications

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver

Evidence-Based Treatment of Primary Biliary Cirrhosis

Novel Therapies on Primary Biliary Cirrhosis

Contact Info

Product

Resources

About